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UNDERSTANDING FACILITATORS AND BARRIERS TO CONTRACEPTION 
SCREENING AND REFERRAL IN YOUNG WOMEN WITH CANCER 
SARAH FRASER LINDSAY 
ABSTRACT 
Background: Young women with cancer often worry about impaired fertility after 
treatment but can experience devastating consequences from an unplanned 
pregnancy during treatment. Contraception screening and referral appear to 
occur infrequently in cancer care. 
Objectives: We sought to understand oncologic providers’ current practices, 
perceptions of facilitators and barriers to screening for adequate contraception 
during cancer treatment, and to understand patient perspectives on these 
processes. 
Methods: We interviewed 19 oncologic providers and 20 female reproductive-
aged oncology patients stable on treatment or who had completed therapy within 
the last 24 months. We recruited participants from an urban, northeast medical 
center where they worked or received oncologic care. Semi-structured interview 
questions examined components of the Promoting Action on Research 
Implementation in Health Services (PARiHS) framework, and subsequent 
constant comparative analysis identified similar themes.  
Findings: Providers vary significantly in their current contraception screening 
practices with many focusing on diagnosing pregnancy rather than prevention. 
Providers identified many institutional and organizational barriers, including lack 
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of education and lack of clear provider responsibility. Providers also identified 
resources and supports that would assist with contraception screening and 
referral, including education and enhanced interdisciplinary collaboration with 
gynecologic providers. Patients infrequently recalled contraception conversations 
with oncology providers and expressed challenges determining the most 
appropriate provider with whom to discuss contraception.  
Conclusion: Cancer centers should address barriers to contraception screening 
and referral locally in future implementation of contraception screening and 
referral. National organizations should work to develop guidelines to inform and 
support this process in clinical practice. 
  
 vi 
 
TABLE OF CONTENTS 
 
ABSTRACT .........................................................................................................iv 
TABLE OF CONTENTS ......................................................................................vi 
LIST OF TABLES .............................................................................................. viii 
LIST OF ABBREVIATIONS .................................................................................ix 
1. Background .....................................................................................................1 
2. Methods ...........................................................................................................6 
2.1. Objectives and Research Questions.......................................................6 
2.2. Design and Methodology .........................................................................8 
Study Design and Conceptual Framework .....................................................8 
General Methodological Approach and Recruitment Processes ....................9 
Data Analysis ...............................................................................................13 
3. Findings .........................................................................................................14 
3.1. Description of study sample ..................................................................14 
Providers ......................................................................................................14 
Patients ........................................................................................................14 
3.2. Overview of qualitative themes .............................................................15 
3.3 Significant variation exists among current contraception counseling 
practices .........................................................................................................15 
Providers report specific recommendations or challenges to contraception 
discussions ..................................................................................................19 
Some providers focus on diagnosing pregnancy .........................................20 
3.3. Institutional and organizational barriers to contraception screening 
and referral exist ............................................................................................21 
Lack of clear provider responsibility for contraception .................................22 
 vii 
 
Lack of education about reproductive health among providers ....................26 
Need for improved interdisciplinary care for contraception ..........................29 
3.4. Provider perception of needed resources and supports to improve 
contraception screening and referral ..........................................................32 
Development of Contraception Screening Tool ............................................33 
Providers and patients requested access to patient-facing resources to 
facilitate contraception screening and referral..............................................36 
4. Discussion .....................................................................................................38 
Evidence ......................................................................................................38 
Context.........................................................................................................41 
Facilitation ....................................................................................................43 
4.1. Suggestions for improvement ...............................................................43 
Provider education .......................................................................................44 
5. Limitations .....................................................................................................47 
6. Conclusion.....................................................................................................49 
Tables .................................................................................................................51 
Bibliography ......................................................................................................53 
Curriculum Vitae ...............................................................................................56 
 
  
 viii 
 
LIST OF TABLES 
 
Table 1. Provider Demographics………………………………………………...….. 51 
Table 2. Patient Demographics……………………………………………………… 52 
  
 ix 
 
LIST OF ABBREVIATIONS 
APC – Advanced practice clinician 
ASCO – American Society of Clinical Oncology 
AYA – Adolescent and young adult 
GYN – gynecologist  
IUD – intrauterine device  
NCCN – National Comprehensive Cancer Network 
NP – Nurse practitioner 
PARiHS – Promoting Action on Research Implementation in Health Service 
PCP – primary care physician  
RN – registered nurse
1 
 
 
1. Background 
Adolescents and young adults (AYAs) who are diagnosed with cancer, defined 
by the National Cancer Institute as patients aged 15-39 years, have multiple 
challenges and stressors throughout their treatment course (Fridgen et al., 2017). 
With regard to family planning, the possibility of impaired fertility after cancer 
treatment is often at the forefront of these concerns (Fridgen et al., 2017). The 
American Society of Clinical Oncology (ASCO) and National Comprehensive 
Cancer Network (NCCN) encourage oncology providers to counsel these 
patients about fertility conserving interventions prior to initiating their cancer 
therapies (Loren et al., 2013; National Comprehensive Cancer Network, 2013). 
The NCCN also recommends contraceptive screening and counseling (National 
Comprehensive Cancer Network, 2013); however, these national organizations 
offer little guidance for screening and referral. Additionally, no recommendations 
exist for subsequent screening for adequate contraception in the post-treatment 
state, particularly for those cancers, such as breast and melanoma, in which 
providers may recommend delaying pregnancy for 2 years after completion of 
treatment (Guth, Huang, Bitzer, Tirri, & Moffat, 2016).  
 
Unintended pregnancy is common in this age group, but pregnancy rates in 
patients undergoing active cancer treatment are unclear (Murphy, Klosky, 
Termuhlen, Sawczyn, & Quinn, 2013). Many are counseled to avoid or delay 
pregnancy until after they complete treatment (Quinn, Letourneau, & Rosen, 
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2014) but continue to have similar rates of sexual activity compared to their 
healthy peers (Klosky et al., 2012). AYAs with cancer and those who have 
completed treatment infrequently use adequate contraception despite ongoing 
fertility (Fridgen et al., 2017; Guth et al., 2016; Maslow et al., 2014; Patel & 
Schwarz, 2012), which may increase the risk of unintended pregnancy (Quinn et 
al., 2014). An unplanned pregnancy during cancer treatment has the possibility of 
significant morbidity for both the patient and the fetus due to treatment delays 
and teratogenicity, respectively, adding to the stress of a new cancer diagnosis 
(Guth et al., 2016). These concerns highlight the importance of adequate 
reproductive life planning and contraceptive counseling in this population; 
however, the best timing, setting and provider to lead these conversations is 
unclear (Fridgen et al., 2017; Quinn et al., 2014).  
 
Contraceptive counseling appears to improve uptake in patients with cancer 
during treatment. A survey-based study found that AYAs with cancer were six 
times more likely to use adequate contraception if they received counseling from 
a health care provider prior to treatment (Maslow et al., 2014). However, Quinn et 
al. (2014) found that pre-treatment counseling did not improve post-treatment 
contraception use, suggesting the need for continued assessment of pregnancy 
intention and contraception utilization during survivorship.  
 
Many barriers exist to adequate contraception use during and after cancer 
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therapy. For patients, counseling regarding post-treatment infertility may suggest 
a lack of need for contraception (Fridgen et al., 2017), and patients or their 
providers may perceive irregular or absent menstruation as therapy-induced 
sterility (Quinn et al., 2014). In one study, 55% of women thought they were 
infertile due to prior cancer therapies despite up to 75% of these women 
continuing to menstruate after treatment (Patel et al., 2009). Additionally, patients 
may not be comfortable discussing reproductive health with their oncologist or 
may choose not to because of misconceptions regarding fertility (Fridgen et al., 
2017). For providers, lack of sufficient knowledge and attitudes regarding 
reproductive health may be detrimental to adequate counseling (Fridgen et al., 
2017), and many do not incorporate this counseling into their practice (Guth et 
al., 2016; Laurence, Gbolade, Morgan, & Glaser, 2004). Finally, providers may 
recommend the discontinuation of certain contraceptive methods whether or not 
cancer-specific contraindications exist, without initiating alternative methods 
(Guth et al., 2016).  
 
Improving the coordination of care between oncologists and reproductive health 
providers is crucial for optimal care for AYAs with cancer. A needs assessment 
surveyed breast cancer patients and providers in Switzerland and found 62% of 
patients needed contraception counseling at time of diagnosis (Guth et al., 2016). 
Ninety percent of providers reported discussing contraception prior to starting 
adjuvant therapy but only 20% counsel, assess for method use during therapy, 
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and refer appropriate patients to gynecology providers (Guth et al., 2016). Patel, 
Tadeke, Uy and Zaren (2011) completed a pilot study of a new algorithm to 
screen for fertility and contraceptive needs in 11 patients with newly diagnosed 
cancer. The authors found this algorithm effective in developing a basic 
reproductive life plan and post-treatment contraception, and the authors are 
designing a larger randomized trial to further test their intervention (Patel et al., 
2011). This algorithm may not be applicable to providers in a setting without 
specialized family planning services, so additional options are needed to further 
address this need. The Society of Family Planning recommends a 
multidisciplinary approach in which primary care providers, oncologists, 
obstetrician-gynecologists and family planning specialists work to address the 
individual reproductive needs of AYAs with cancer (Patel et al., 2012). 
 
A systematic review by Fridgen et al. in 2017 describes current knowledge 
regarding barriers to contraception counseling in this population and found 
significant overlap among the barriers present in both patients and providers. 
Both patients and providers exhibited lack of knowledge regarding contraceptive 
needs in this population due to an emphasis on fertility preservation counseling 
and the presence of oligo- or amenorrhea during or after treatment. The authors 
also suggest that both patients and providers had difficulty in addressing “sexual 
topics” in this age range, limiting both groups’ willingness to discuss 
contraception, particularly in the adolescent age range. In particular, a study of 
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oncologic nurses suggests this discomfort with these topics. The authors 
encourage the development of improved guidance and training for oncologic 
providers to better address this issue and call for ongoing contraception 
screening and counseling throughout cancer care for this age group. 
 
While contraception counseling by oncologic providers appears to improve 
utilization during treatment, few such providers incorporate this counseling into 
their practice (Guth et al., 2016; Johansen, Lerma, & Shaw, 2017). Aside from 
provider misconceptions regarding fertility during and after treatment, few studies 
have considered provider-specific barriers, and few have queried United States-
based providers. Our study aimed to expand knowledge regarding current 
practices, facilitators and barriers at an academic medical center to guide future 
implementation of strategies to improve this process.  
 
Fridgen et al. (2017) found minimal data regarding patient preferences for 
contraception counseling, which highlights the importance of including patients in 
our investigation. One recent study of women with breast cancer found that 
patients infrequently recalled reproductive health discussions by their 
oncologists, and that patients want information about contraception from their 
oncologist soon after diagnosis (Mody, Panelli, Hulugalle, Su, & Gorman, 2017).  
 
Additionally, the majority of previous studies on contraception in AYAs with 
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cancer, including all the studies described by Fridgen et al., utilized quantitative 
methodologies. The paucity of data regarding barriers to contraception 
counseling and referral for both patients and providers suggests the need for a 
qualitative approach to better understand these factors.  
 
Previous studies have identified low contraception utilization rates in female 
AYAs with cancer, but none have determined how to improve screening and 
referral in this clinical setting. Through this qualitative study, we aimed to explore 
the full scope of barriers and facilitators to contraception screening and referral 
for both oncologic providers and their patients.  
 
2. Methods 
2.1. Objectives and Research Questions 
Our objectives for this research project were as follows: to understand providers’ 
current practices for contraceptive screening and referral practices within a single 
cancer center at an urban, northeast medical center; to identify providers’ 
perceptions of facilitators and barriers to these practices in the clinical setting; 
and to understand patient perspectives on contraception counseling during and 
after cancer treatment. We used qualitative methodology to assess these aims 
and explore participants’ recommendations of supports that may be implemented 
to improve contraception screening and referral and assess factors within the 
cancer center to support such implementation. This project is the first step of 
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many in the implementation process, to be followed by development of clinical 
supports, testing of these supports, development of a toolkit, disseminating 
findings at a local and national level to support widespread implementation and 
expansion of national guidelines.  
 
The research questions for this study were as follows: 
1. What is the current status of contraception screening and referral in the 
cancer center? 
a. How do oncology providers currently counsel and assess for 
contraception utilization during and after treatment?  
b. What are the patients’ experiences and preferences regarding 
contraception screening and referral while undergoing cancer treatment?  
2. How does the cancer center enact changes in clinical practice? 
a. How does the culture of the cancer center affect implementation of new 
policies and practices? 
b. What methods have been successfully or unsuccessfully utilized to 
improve contraception screening and referral in this center? 
3. What are the barriers and facilitators to contraception screening and referral in 
this center? 
a. What skills or specific roles exist in the cancer center that may support 
implementation of contraception screening and referral? 
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b. How does the clinical workflow affect contraception screening and 
referral in this setting?  
This study was designated exempt from the Boston University Institutional 
Review Board. 
 
2.2. Design and Methodology 
Study Design and Conceptual Framework 
This study is a pre-implementation assessment of current practices, facilitators 
and barriers to contraception screening and referral to determine the appropriate 
needs of this cancer center. We designed this study around the Promoting Action 
on Research Implementation in Health Services (PARiHS) framework, as 
implementation science frameworks specifically and systematically identify the 
factors that influence integration of research findings or policy recommendations 
into health care in a given setting in order to “improve the quality and 
effectiveness of health services and care” (Bauer, Damschroder, Hagedorn, 
Smith, & Kilbourne, 2015; Rycroft-Malone, 2004). Implementation science 
actively assists in translating evidence-based recommendations into clinical 
practice by identifying barriers and facilitators to widespread application of a 
recommendation and creating appropriate adaptations to improve uptake (Bauer 
et al., 2015; Nilsen, 2015). Though we did not implement a specific intervention 
in the present study, utilizing this approach assisted in identifying current 
practices and needs in order guide future implementation studies.  
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While there are several frameworks within implementation science, the PARiHS 
framework is ideal because it acknowledges that successful implementation 
relies on the interaction between evidence, context, and facilitation (Rycroft-
Malone, 2004). Within this framework, evidence consists of research findings 
from well-designed research studies, but also clinical experiences, patient 
experiences, and local information. Context assesses the settings’ culture, 
leadership, and evaluation and their respective influences on implementation. 
Facilitation identifies specific roles, skills and attributes that may assist or 
dissuade implementation within a given setting (Rycroft-Malone, 2004). The 
strength of each element helps in successfully implementing a new concept 
(Rycroft-Malone, 2004). The study aims and research questions focused on 
these factors, with research question 1 addressing evidence, research question 2 
addressing context, and research question 3 addressing facilitation. 
 
General Methodological Approach and Recruitment Processes 
We conducted semi-structured qualitative interviews with provider participants in 
the various departments in this cancer center. Eligible participants included 
current employees who self-identified as physicians, advanced practice clinicians 
(APCs), registered nurses (RNs), and care coordinators involved in oncologic 
patient care of young women with cancer. We purposively sampled from both 
medical and surgical oncologic fields as well as by provider type. We recruited 
providers through a variety of strategies, including through advertisements at 
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faculty meetings and email invitations aimed at oncologist participants. We also 
conducted snowball sampling with recommendations from other provider 
participants. 
 
After obtaining verbal consent and collecting demographic data, we asked each 
provider participant broad questions regarding contraception and fertility 
counseling practices at initial diagnosis and during follow up care, followed by 
more targeted questions focused on reproductive health in young women with 
cancer and prior implementation experiences in their current practice setting. At 
the conclusion of the interview, each provider participant was given a $50 gift 
card for their participation. 
 
We also performed individual interviews with patient participants aged 18-45 
years who were stable on treatment or had completed cancer treatment within 
the last 2 years at the cancer center. We initially planned to recruit only patients 
who had completed treatment but expanded our recruitment to include patients 
stable on active treatment, as determined by their oncologist, at the suggestion of 
oncology providers to assist with recruitment. We chose to extend the age range 
from the traditional definition of AYA with cancer, as has been expanded in prior 
studies on reproductive health in this population, in order to include all patients of 
childbearing age (Fridgen et al., 2017). We chose to exclude patients under 18 
years of age because we anticipated unique barriers to contraceptive services 
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with this population, which are outside of the scope of this study. We defined 
completion of cancer treatment as surgery (if no adjuvant treatment was given or 
indicated), end of radiation, or end of intravenous chemotherapy as is deemed by 
the patient’s oncologist. For patients on active treatment, we queried their 
primary oncology provider to determine stability on treatment prior to contacting 
the patient to offer participation. We included patients on oral agents (i.e. 
tamoxifen) or maintenance chemotherapy (i.e., avastin maintenance). Exclusion 
criteria were: all oncologic care received at another site; non-English speaking 
patients; patients who were deemed sterile at the time of cancer diagnosis (i.e. 
prior bilateral tubal ligation, bilateral oopherectomy, or hysterectomy), and self-
report of lack of prior, current or planned heterosexual intercourse.  
 
We identified eligible patient participants through a variety of strategies. With 
provider permission, a member of the research team reviewed clinical schedules 
to identify potentially eligible participants and approached them in-person after 
their scheduled appointment to screen and offer enrollment. We also identified 
potentially eligible patient participants using an electronic medical record query 
utilizing cancer diagnosis codes, age and reported gender; we also queried the 
institution’s tumor registry to identify potentially eligible patients in a similar 
fashion. With their treating provider’s permission, we mailed letters inviting 
patients to participate and performed a follow-up phone call to screen and invite 
eligible patients to participate.  
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After obtaining verbal consent and collecting demographic data, we conducted 
semi-structured interviews using a separate interview guide with questions linked 
to the components of the PARiHS framework. These interviews mainly targeted 
evidence within the PARHiS framework, specifically patient experiences with 
contraception screening and utilization during and after cancer treatment, 
including patient preferences and access to contraception. Additionally, the 
interview questions addressed facilitation by assessing the patient’s perspective 
on her prior experiences with the oncology team and any perceived barriers to 
contraception access related to her care. At the conclusion of the interview, each 
patient participant was given a $50 gift card and offered $10 for transportation for 
their participation. The interview guides were modified in an iterative fashion 
based on analysis of the initial interviews with each participant group. 
 
Two members of the research team trained in qualitative methodology conducted 
all interviews. One team member, a female obstetrician-gynecologist, performed 
all provider interviews. Another team member, a female research assistant, 
performed all patient interviews. All participants provided verbal consent 
immediately prior to starting the interview. Interviews were complete in person in 
a private room within the cancer center or hospital. All interviews were audio-
recorded and professionally transcribed verbatim. A member of the research 
team reviewed each the transcripts for accuracy and removed any identifying 
participant information. The transcripts were then analyzed using standard 
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qualitative research methods, specifically using directed content analysis with the 
PARiHS framework and constant comparison methods, using the NVivo Version 
11.0 Software (“NVivo qualitative analysis software,” 2016) for data 
management.   
 
Data Analysis 
The analysis of each transcript occurred in tandem with the interview process, 
using directed content analysis as described by Hsieh and Shannon (Hsieh & 
Shannon, 2005) and constant comparative methods (Boeije, 2002) to direct 
participant sampling and refinement of the interview guides iteratively, as 
needed. Using open coding, two trained members of the research team 
independently coded each transcript line by line using direct content analysis. 
Components of the PARiHS framework guided the naming and defining of codes.  
As new concepts arose from the data, the coding team added new codes to the 
codebook. The two researchers compared codes and resolved differences with 
discussion and review of coded quotes from the interview transcripts and the 
code as defined in the codebook. When discrepancies occurred, a third 
researcher analyzed the transcript and codebook to achieve consensus.  
 
In total, we identified 27 open codes that were based on the constructs of the 
PARiHS framework (Rycroft-Malone, 2004), including these examples: 
“evidence-clinical experience-lack of knowledge”, “evidence-research”, and 
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“context-leadership”. We reviewed 21 of these codes during axial coding, only 
including the codes that were identified in two or more interview transcripts. We 
categorized related axial codes and reviewed within the PARiHS framework to 
identify underlying themes.  
 
3. Findings 
3.1. Description of study sample 
Providers 
In total, we interviewed 19 providers, 58% of whom were physicians, 21% were 
advanced practice clinicians (APCs) including nurse practitioners (NPs) and 
physician assistants, and 21% were registered nurses (RNs). The median age 
was 42 years (range 28-63). Among the physicians and APCs, 53% were from 
surgical specialties (including surgical oncology, gynecologic oncology, colorectal 
surgery, and oral maxillofacial surgery and otolaryngology). The remaining 47% 
were from medical specialties (including hematology/oncology, endocrinology, 
and dermatology). Table 1 describes the basic demographics of provider 
participants.  
 
Patients 
In total, we interviewed 20 patients. The median age was 34.5 years (range 23-
45), with 35% younger than 30 years. Half of the patient participants had children 
and half had an individual annual income less than $20,000. Approximately 35% 
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had thyroid cancer and 15% had breast cancer. Table 2 describes the basic 
demographics of patient participants. 
 
3.2. Overview of qualitative themes 
Three themes emerged from the individual interview data relating to both 
providers’ and patients’ perceptions about contraception screening and referral in 
the cancer center. Primary themes included: significant variation between 
providers’ current screening and counseling for contraception use during cancer 
treatment, existence of institutional and organizational barriers for contraception 
screening, and provider perception of needed resources and supports to improve 
contraception counseling.  
 
3.3 Significant variation exists among current contraception counseling 
practices  
Providers infrequently counsel patients to use contraception to avoid pregnancy 
Providers vary significantly on their current contraception screening and referral 
practices. While many providers recognized the importance of avoiding 
pregnancy during cancer treatment, most providers report infrequently 
counseling patients to use contraception to prevent pregnancy. For example, one 
surgical oncologist responded:  
“No. We probably should but no.  In fact, it’s funny because we have 
patients, I mean, it’s not funny, but the patients show up either to their 
preoperative visit and then on the morning of surgery and they have the 
pregnancy test. So then if they’re pregnant, their operation gets canceled.  
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So no, we don’t and we should obviously tell our reproductive age 
patients, “Don’t get pregnant between now and surgery because you have 
cancer’” Provider 9, physician, surgical oncology 
 
Other providers limit their counseling to “warning” patients to avoid pregnancy or 
to avoid intercourse during their cancer treatment. A medical oncologist stated:  
“Honestly, usually, I limit it to like, you shouldn’t be having sex while you’re 
neutropenic and that’s just a tiny part of the conversation about like, don’t 
eat undercook meat and ham like – it’s like once and sandwiched in there 
with all of these other things. It’s not often on people’s minds. Every once 
in a while, someone will ask about it but, not usually” Provider 3, 
physician, medical oncology. 
 
Some patients similarly recall such warning from their providers: “The only 
conversation on birth control is that they don’t want me to get pregnant at all. 
That’s always been the conversation” Patient 8. 
 
Clinical factors impacting contraception discussions 
Few providers routinely discuss contraception at the initial visit while some will 
discuss contraception under specific situations, including in response to a 
patient’s inquiry or if the planned treatment is teratogenic. Others rely on other 
clinical data such as the medication list or identification of an intrauterine device 
on a CT scan to assess contraception use at the initial visit: “We go through the 
medication list… And then we always have staging CT scan so I can see if they 
have an IUD” Provider 14, physician, surgical oncology. Those providers who do 
discuss contraception initially do not assess compliance during cancer care. 
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Some providers discuss prior contraception use while assessing risk factors for 
certain cancers but do not ask about current contraception use for pregnancy 
prevention. Some providers assume that the patient’s primary care provider or 
another provider has addressed contraception prior to her appointment with the 
oncologist:  
“I don’t know. I mean, most women of that age like, have had that 
conversation with somebody before and it’s like, if they were actively trying 
to get pregnant, they probably would have mentioned it. If they don’t, I 
assume that they are already know about birth control and planned to not 
get pregnant” Provider 3, physician, medical oncology. 
 
One surgical provider perceives that abstinence is “implicit” in the counseling:  
“I suppose I’m not that good at doing that… We try to expedite the 
surgery. So, I must admit that I don’t really always bring [contraception] 
up. I think that maybe it’s implicit in our discussion that they wouldn’t be 
having intercourse… I don’t– I don’t always explicitly talk about preventing 
pregnancy” Provider 13, physician, surgical oncology.  
 
Other providers never or rarely discuss contraception and question if they should: 
“I don’t think I have frequent conversation about contraception…Should I be?... I 
don’t have those conversations... I don’t think it’s come up” Provider 5, physician, 
surgical oncology. 
 
Methods of contraception 
Providers also vary as to which specific contraceptive methods, if any, they 
discuss with patients. Some providers do discuss specific contraceptive methods, 
with a focus on lower-efficacy methods including abstinence, condoms, and 
condoms plus spermicide. One provider recommends dual method use for 
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improved contraceptive efficacy. Others recommend leuprolide acetate (Lupron) 
for contraception:  
“Our breast cancer patients, we try to make sure they do not get pregnant 
during treatment because that can make their cancer worse coz the 
hormones can make it worse. So we usually try to keep on that and make 
sure they are getting either [Lupron] injections here or using some kind of 
birth control at home and really stressing to them that this is not the time 
to get pregnant” Provider 15, nurse, medical oncology.  
 
Some providers discuss condom use or abstinence for specific indications other 
than pregnancy prevention, such as for infection prevention, to prevent bleeding 
complications during periods of neutropenia or thrombocytopenia. Some 
providers counsel patients on a specific timeframe during treatment or after 
treatment to avoid pregnancy, but do not counsel on specific methods:  
“I usually warn people at the end of chemotherapy that you may not be 
having periods now but, that doesn’t mean that you’re not fertile… I’ve 
started like warning people about it and you may not think you’re fertile 
but, you are… You really should use contraception” Provider 3, physician, 
medical oncology.  
 
 
Patients’ perceptions of counseling 
Patients similarly recall participating in contraceptive counseling to avoid 
pregnancy without a discussion of contraception options:  
“He said, “Don’t get pregnant for six months,” and I said, “Okay, I won’t.” 
He said, “Yeah, you can say that, but then in four months, you’ll be calling 
me that you’re pregnant.” Looking back, maybe that wasn’t a real 
constructive conversation. Maybe he could have offered me some 
alternatives or something or more advice other than you’re going to be 
pregnant in four months; it happens all the time” Patient 5. 
 
No providers recall prior contraceptive screening programs at this cancer center. 
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Those who have worked or trained elsewhere note that other institutions with 
more streamlined referral processes or dedicated patient navigators help to 
identify reproductive health needs, including contraception, to make this process 
“seamless”:  
“There they had a very well-developed program, so it was like a routine 
referral for everybody… The doctor or the nurse would identify patients 
who were eligible and would discuss whether or not they wanted to pursue 
the referral, the patient, and then there was a very streamlined referral 
process for that. It's a totally different system there… the care team is a lot 
more robust” Provider 12, physician, surgical oncology. 
 
Providers report specific recommendations or challenges to contraception 
discussions 
Some providers recall specific challenges to discussing contraception with 
women with cancer. One provider recalled discussing contraception with a 
patient with cancer:  
“I think the majority of that conversation was kind of less about the types 
of contraceptive and more about… just convincing her that she needed to 
do it and that the risks to her and the baby were very high if she…didn’t” 
Provider 2, physician, medical oncology.  
 
 
Providers reported difficulty “convincing” a patient to use contraception 
particularly with patients with pre-existing infertility, those actively seeking 
pregnancy at diagnosis or those who have completed childbearing with 
impending sterility due to treatment. Providers also recalled difficulty with 
uncertainty of a patient’s ability to negotiate contraception use with her partner 
(i.e. with condoms) and the provider’s lack of sufficient time to devote to 
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contraception discussion. Some female providers perceive their gender to 
positively impact the ease of these conversations compared with their male 
counterparts:  
“I think in general, I think we’re good. I think we’re pretty comfortable with 
it. But, part of it- or most of it, is probably that most of our providers are 
female. I think most of us sort of know what is out there. It’d be a different 
question, I think, to a male provider, whether they know all the possibilities 
that are out there” Provider 10, female, physician, medical oncology.  
 
Patients similarly perceive female providers as more knowledgeable of 
reproductive health needs: “It might be worth pointing out that most of my doctors 
are older men, so maybe it doesn’t give me the most confidence in their birth 
control knowledge” Patient 5. 
 
Some providers focus on diagnosing pregnancy 
When asked about current practices discussing reproductive health and 
contraception with reproductive-aged women, some providers focus on 
diagnosing current pregnancy and not preventing pregnancy: “We check 
pregnancy tests multiple times along the treatment path, but I don’t actually tell 
them what to use” Provider 10, physician, medical oncology. Specifically, some 
providers routinely ask each patient during a visit whether she is currently 
pregnant and perform frequent pregnancy tests as a safety check. These 
providers focus on current pregnancy to dictate appropriate diagnostic and 
therapeutic modalities in the context of cancer care:  
“Once they’ve been identified as having cancer, we normally, we ask them 
or I ask them if they are pregnant or planning to become pregnant and 
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that’s usually the extent of it and we sort of focus on the treatment for the 
cancer. Once they’ve finished their surgical part of the treatment we rely 
on medical oncology to talk more about their options in terms of fertility 
and contraception. I don’t really spend that much time on contraception” 
Provider 4, APC, surgical oncology.  
 
Additionally, other providers recall frequent pregnancy tests during care, 
particularly at the time of surgery or prior to initiating a teratogenic treatment, 
such as radioactive iodine.   
 
Many patients do not recall specific or direct counseling by a provider to use 
contraception or to avoid pregnancy during treatment, but do recall frequent 
pregnancy tests during their care, despite reported strict abstinence. Some 
patients interpret these frequency pregnancy tests as an indication from their 
providers that pregnancy was not recommended during care: 
“I assumed based on just my own perception, not even as someone who 
had cancer, but just as what I perceived that people with cancer must do. 
So, no education, just people with cancer shouldn't try to get pregnant, 
and therefore, I based my decision on that. Maybe that's even a fallacy. I 
don't know. All I know is they do pregnancy test me every single time I 
have a procedure done. I'm assuming it's not a good idea to get pregnant” 
Patient 6. 
 
 
3.3. Institutional and organizational barriers to contraception screening and 
referral exist 
Although few providers screen and refer reproductive-aged female patients with 
cancer for contraception counseling, providers report multiple barriers that further 
challenge this referral process. These barriers include lack of clear responsibility 
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for contraception, lack of education about reproductive health, and lack of 
national and institutional guidelines. 
 
Lack of clear provider responsibility for contraception 
Findings suggest that interprofessional care teams are often used within many 
practices at this cancer center; however, many providers assume that another 
member of the care team discusses contraception and pregnancy prevention 
with patients. For example, surgical oncologists assume that medical oncologists 
discuss contraception because medical oncologists give teratogenic treatment, 
i.e. chemotherapy: “I think honestly though, as in the surgical field, we probably 
would either consciously or subconsciously turf that off to like the person that's 
administering the chemo or radiation” Provider 8, APC, surgical oncology. Other 
providers defer contraception discussions to a patient’s primary care provider or 
gynecologist:  
“We defer to PCPs… We have a patient navigator. We can help them get 
into PCP, who can contact the PCP to get them in… It doesn’t come up all 
that often… Honestly, most patients when they come in were pretty 
focused on…their cancer” Provider 4, APC, surgical oncology. 
 
In addition to oncologists, providers presume that oncologic pharmacists counsel 
patients about contraception prior to dispensing oral chemotherapy: “Honestly, 
we defer a lot of that stuff onto the pharmacist… pharmacists are the ones that 
tend to deal with it” Provider 3, physician, medical oncology. Nursing participants 
reported they assume the physician or APC has discussed contraception prior to 
initiating treatment and presume patients prefer discussing contraception with 
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physicians:  
“Well I think the doctors for the breast cancer patients, at least I think they 
discussed that in their initial meetings with their patients. So I think that 
comes up probably quite frequently with the physicians. But the nursing 
staff, not quite so much. I think it’s more addressed there and a lot of 
times the patients feel more comfortable asking their doctors because they 
think that they probably know more about what they should and shouldn’t 
be doing” Provider 15, nurse, medical oncology. 
 
When asked who should be responsible for discussing contraception, providers 
presented varying views as well. Some participants reported the provider who 
interacts with the patient most frequently should be responsible. Nursing and 
APC participants report the responsibility should be shared between multiple 
providers on the care team and may change over time as the patient proceeds 
through care. For example, physicians could initiate the conversation with 
patients and then either a nurse or APC, who often have existing close 
relationships with patients, could follow up and offer patient additional education 
when needed.  
“I think the conversation should start with - usually the patients are with 
the nurse a lot and they do, because we see them very frequently, we kind 
of develop a bond so I think that would probably the starting point, but I 
definitely know that I would need to get more help in dealing with the 
situation” Provider 16, nurse, medical oncology. 
 
Medical providers view surgical providers as responsible for contraception 
perioperatively, and report that medical providers are responsible during adjuvant 
treatment: 
“I do not make sure before the surgery, but I will- I feel like I’m the 
responsible person after the surgery… That’s when I assume care and 
that’s when we start having the conversations about pregnancy… Alright, 
you had a lot of cancer. We think we’ve taken most of it out but that 
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increases your risk- it’s going to come back. We’ll know, probably, within 
the first year. It’s really important that you don’t get pregnant during that 
time” Provider 10, physician, medical oncology. 
  
 
Overall, provider participants lacked consensus on the utility of asking patients 
about contraception and their use of a method over time. 
 
Provider participants also reported that perhaps the person who diagnoses 
cancer or starts treatment should be responsible for contraception screening and 
referral:  
“Yeah, and who's gonna give the treatment that might hurt a fetus from -- 
or who's gonna be giving the first treatment where the patient might be 
getting pregnant during that time” Provider 14, physician, surgical 
oncology.  
 
Other providers report it is ultimately the patient’s primary care provider should 
be responsible for ensuring contraception use during cancer treatment.  
 
Patients also lack clarity as to with which care provider they should address 
contraception and cite various factors that would influence their decision on 
which provider to approach with such questions. Some patients specifically 
preferred to discuss contraception with an oncology provider because these 
providers develop their plan of care: 
“Interviewer: If you wanted to make a change to your birth control method 
at this point, who would you reach out to? 
Interviewee: Oncologist… When it comes to making a decision on how to 
deal with the cancer, I would go to the oncologist and ask her what would 
be her recommendations versus my gynecologist. I want someone to 
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make the right decision for my health long-term, not just okay, am I ready 
to reproduce. That’s a little more short-term. I would recommend my 
oncologist” Patient 8. 
 
Other patients preferred a particular member of their oncologic team because of 
a certain characteristic, including female gender, openness to questions in 
general, ease of communication outside of a visit (i.e. with email), empathetic 
nature of the provider, or perceived knowledge about contraception in the context 
of cancer. Patients perceived that female or older providers have more 
knowledge about contraception. Other patients prefer discussing contraception 
with their gynecologist or primary care provider because these providers are 
perceived to be experts in this topic and have previously addressed 
contraception with patients:  
“Interviewer: If you had a choice of like provider just to talk with or 
anybody to talk to about reproductive health, who do you think you would 
choose?  
Interviewee: A gynecologist… I just feel like they're the trusted source.  
They have the knowledge and the resources, experience of other patients 
and stuff” Patient 1. 
 
Other patients recall infrequently interacting with their primary care provider 
during cancer treatment. Some patients express uncertainty on the appropriate 
provider with whom to discuss contraception and request assistance with 
identifying the best person in a given care team to discuss these topics: 
“[in reference to reprodutive health questions] Tell me how to ask the right 
doctor if you're not the doctor. Then tell me which doctor. I have a ton of 
doctors, and I don't know which of them to ask which questions. So I get 
frustrated because then I'll ask one of them, and they kind of shrug it off or 
that's strange, I don't know, which doesn't help me. It doesn't make me 
less neurotic about the fact that I have cancer and something else might 
go wrong” Patient 6. 
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Lack of education about reproductive health among providers 
While many providers indicate they are or would be comfortable discussing 
contraception with their patients, many do not engage in these discussions 
because they reportedly lack adequate education and training or expertise 
around sexuality, contraceptive options, and fertility preservation particularly in 
the setting of cancer care: “Well, to tell you the truth, I would feel fine with it, but I 
feel like we're not really that well-educated on it ourselves” Provider 17, nurse, 
medical oncology.  
 
While many providers were open to contraception-specific education, one 
surgical provider does not find this lack of knowledge impacts the safety of the 
care provided:  
“Probably I know less about that because I didn’t have any formal 
training... I may be a little bit but of an outlier in terms of who needs what? 
But also my day-to-day existence, it doesn’t really impact me because the 
medical oncologists deal with that… Which obviously we’d all like to know 
more and I wish I knew but I can do safe operations on my patient without 
knowing it so that’s where I am right now” Provider 9, physician, surgical 
oncology. 
 
When providers lack education or knowledge about other clinical topics, they 
reported they will reference established national association guidelines or similar 
references to guide their practice:  
“I probably learn it best if I have some kind of summary or guideline or 
something that’s available to me to look each time that I need it…having 
something that’s easily accessible to take a look at each time that -- that I 
see a patient with that issue is probably the easier thing.  Because as it is, 
I just re-look through all the…literature every time something like this 
comes up, but having some kind of quick reference, guide, or something 
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that’s available… I think would be better for me personally” Provider 2, 
physician, medical oncology.  
 
These providers report a lack of available established national association 
guidelines about contraception and other reproductive health issues affecting 
young women with cancer, including consensus guidelines on include the utility 
of Lupron for ovarian suppression, whether additional contraception is 
recommended concurrently with Lupron, and recommendations for safe 
pregnancy timing after completion of treatment to facilitate contraception 
counseling. Providers suggest that the availability of such resources would 
augment providers’ knowledge and ability to engage in contraception screening 
and referral.  
 
Nursing participants also suggest that an institutional guideline about 
contraception screening and referral would help ensure that members of the care 
team more frequently address contraception with women in this age range:  
“We don’t even have like guidelines on what should be done [for 
contraception screening].  I think there have to be something that could 
help the cancer care center in general as to have some type of guidelines 
or booklet or something that should be given to that population” Provider 
16, nurse, medical oncology. 
 
A select few providers increased their contraceptive knowledge through 
fellowship experiences. More often, providers gain information about 
reproductive health from clinical and personal experiences:  
“A lot of the information I just kinda pick up when I'm listening to the 
physicians talk, and I will very often refer to the physicians if there's any 
specific questions” Provider 17, nurse, medical oncology. 
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“Well I think we would want to know the most current… I mean a lot of us 
here in this clinic, out of the women here, are over 50. So lot of us are not 
of reproductive years anymore. So we're probably out of the loop on the 
lot of the newest IUDs or injections or whatever it is they are using. A lot of 
us are out of the loop on that. So it would be nice to have somebody tell 
you the most newest and safest way to go… Years ago it was the pill. It's 
not the pill anymore. So it'll be something nice to hear you know” Provider 
15, nurse, medical oncology. 
 
While certain surgical oncology providers assume medical oncology providers 
have had prior training in reproductive health and contraception, medical 
oncology providers similarly lack formal training in residency or fellowship about 
cancer-related contraceptive information. Providers with a specific background 
related to reproductive health, such as gynecologic oncologists (through 
obstetrics and gynecology training) or endocrinologists (through training around 
benign disorders of the reproductive tract, such as polycystic ovarian syndrome) 
recall education on contraception but not specific to contraception during cancer 
care:  
“Nothing in my training. Absolutely, nothing in my training. I know, internal 
medicine, we really didn’t learn anything about it. I think in my Endocrine 
Fellowship, we learned more about the different types of birth controls and 
what was androgenic and what was not androgenic and what do you do 
for PCOS, so it was sort of by association. And in terms of cancer 
management, no one taught me any of this” Provider 10, physician, 
medical oncology. 
 
In addition to impeding regular discussions about contraception, this lack of 
education leads to providers counseling patients incorrectly about certain topics, 
including decreased efficacy of oral contraceptive pills with antibiotic use and the 
utility of Lupron for contraception. Similarly, patients who have received Lupron 
for ovarian suppression incorrectly perceive Lupron as effective contraception, 
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either through counseling from providers or assuming by the mechanism of 
action of suppressing the menstrual cycle. One patient recalled:  
“I told her I was like on birth control, the Lupron, but then I was reading 
online and then it says it's possible to get pregnant while using Lupron so 
then I was like so then that's not birth control. So, then I don't know. For 
now, I just don't know” Patient 19. 
 
Knowledge barriers among gynecologic providers may exist as well. One patient 
recalls discussing contraceptive options with her gynecologist, who was 
uncertain as to the safety of a given method with the patient’s type of cancer:  
“Yeah so that was the point because we didn’t know if I could put like the 
NEXPLANON at that point because the gynecologist didn’t know. I didn’t 
know exactly if I could put that or could not.  I wasn’t having sex at that 
point…so I was like just focused in my treatment, but the problem then 
was if we, like [the doctor] basically didn’t know if the hormones had any 
like relation with [my type of cancer], so she didn’t know and I couldn’t 
know as well” Patient 16. 
 
Participants preferred a variety of educational formats and topics to address 
contraception in this population. Proposed educational ideas from participants 
include: education about different types of contraception and safety of these 
options during cancer care, skills-based training on discussing reproductive 
health and contraception, and education about available patient- and provider-
facing resources. The providers suggest a variety of formats based on their 
personal learning preferences, including grand rounds, case-based learning, 
continuing education workshops, and email or other written material. Providers 
also identified a need for didactics and case-based learning about how 
interprofessional teams can best service and educate patients with cancer. 
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Providers prefer that such educational opportunities be offer at optimal times (i.e. 
during lunch, early morning before clinical tasks begin). 
 
Need for improved interdisciplinary care for contraception 
Oncology practices at this institution commonly use interdisciplinary teams during 
cancer treatment, with multiple types of providers interacting with a patient at a 
given visit and over time. These providers may include physicians (including 
residents and fellows), advanced practice clinicians (APCs), nurses, medical 
assistants, social workers, medical students, patient navigators, administrative 
assistants, nutritionists, and other allied health professionals. Providers also 
collaborate with others in other disciplines, including medical, surgical and 
radiation oncologists as well as with other consultants such as infertility 
specialists. Providers use these colleagues as sources of information, to help 
clarify educational information, and to explain the recommendations given by 
other providers when the provider lacks expertise:  
“[when the provider has a question, she uses] Email (laughs) or even 
messaging to someone in gynecology.  Honestly, that's the real answer… 
I just prefer that… It's not really the greatest system because then the 
patient came back after seeing gynecology and then I was unsure what 
they had said and I don't know.  The patient was completely unsure of 
what had been said… So then I had to message and ask for some 
clarification about what the plan was… There's a note, but maybe I just -- I 
don't know enough about gynecology to know exactly what the best option 
was based on the options were that were mentioned” Provider 2, 
physician, medical oncology. 
 
Conversely, providers inconsistently utilize contraception specialists during 
cancer care, and infrequently have established relationships with these providers 
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which inhibits contraception screening and referral. 
 
Providers vary as to whom they may refer a patient for contraception counseling. 
Some providers would refer a patient to a provider within the same institution to 
facilitate communication of recommendations from the consultant, while others 
would refer to a provider with whom the patient has an established relationship: “I 
always feel if they have an established relationship, that's one to go with” 
Provider 14, physician, surgical oncology. Other providers prefer to involve 
another provider within the cancer center especially if the patient does not have a 
gynecologist or primary care provider, such as the attending oncologic physician 
(recommended by nurses), or another provider in the cancer center with prior 
experiences in women’s health (such as an APC with this prior experience, 
recommended by a physician):  
“I would ask if she has a gynecologist. If she doesn’t, I mean, there’s a few 
NPs in our practice that – were in primary care or women’s health 
beforehand that I could pull at hand and ask what were to give them or 
something” Provider 3, physician, medical oncology.  
 
The utilization of other providers within the cancer center rather than referral to 
another department suggests lack of education on appropriate providers or lack 
of streamlined process for referral to the gynecology department. 
 
Providers recognize certain facilitators to effective interdisciplinary teamwork 
between departments. These factors include expeditious scheduling of a 
consultation and access to a point person in another section or department to 
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contact directly with question or for scheduling and the availability of a 
contraception clinic for patient referrals.  
 
Patients similarly value an established relationship between her provider and 
consultant, and access to a direct contact in another department to facilitate 
scheduling and to answer questions:  
“Some of my doctors were really good about giving me a number to 
someone in their office that I could call if I thought of questions later 
because they knew I would be overwhelmed. But verbally there's a human 
component to that with the option to call or ask questions on follow up 
appointment” Patient 6. 
 
One provider preferred the availability of a contraception clinic to assist with 
patients understanding the reason for the visit:  
“So, I think, perhaps, if there was a birth control center to refer a patient to, 
specifically for birth control, that might be an easier thing for them to 
understand. Say, you’re going to this doctor for this reason and you must 
go. And then, if we can book it so that I know that it’s booked and they’re 
going, it would be easier. It would be useful” Provider 10, physician, 
medical oncology. 
 
Such a clinic exists at this institution; however, providers lacked awareness of 
this resource available to their patients. 
 
3.4. Provider perception of needed resources and supports to improve 
contraception screening and referral  
Providers identified specific resources and supports that would assist with 
implementation of contraception screening and referral. These resources and 
supports include those identified in previous sections, such as improved 
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education and guidelines, clear roles for contraception screening, and 
strengthened interdisciplinary teamwork, as well as additional resources 
discussed here: development of a contraception screening tool with associated 
patient-facing resources and development of patient-facing resources. 
 
Development of Contraception Screening Tool 
Some providers support the development of a contraception screening tool to 
help identify patients appropriate for referral:  
“I think a short screening tool would be appropriate.  I think it’s just so 
important to have the follow up people for them to meet when… Because 
we bring up these questions and then they’re thinking about contraception 
and they’re asking us what should I do? What should I be on?… We don’t 
necessarily wanna sit down and focus too much on that… Screening tool 
and then one second like don’t worry we’ll set you up with the right person 
to talk more about it” Provider 4, APC, surgical oncology. 
 
Many providers recommended screening for contraception with every patient of 
reproductive age, particularly those with hormonal cancers such as breast or 
gynecologic cancers. 
 
Providers requested resources to support the contraception screening and 
referral process. Available information should include succinct guidelines 
(national or institutional) briefly discussing contraceptive methods, referral 
processes, recommendations for pregnancy timing after treatment. 
 
Specific questions recommended by providers include: asking if the patient is 
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pregnant, if she wants to become pregnant, if she is sexually active or plans to 
be during treatment, and if she is using anything to prevent pregnancy. Some 
providers recommended such tool should include questions about treatment 
duration, recommended waiting period after treatment and lead to a pregnancy 
prevention plan and access of other resources such as consultants. 
 
Providers differed on the appropriate time to screen for contraception. Most 
thought it should occur “early on”, with some providers suggesting at the first visit 
and others at a follow up visit:  
“I feel like, it needs to happen very early but, probably not on the initial 
visit. The focus is on somewhere else and I think it might make sense to 
like have the nurse practitioners or the fellows, somebody…to have like a 
dedicated time to talk about it” Provider 3, physician, medical oncology.  
 
Patients preferred to have this information early on in their treatment:  
“I guess one thing that would be helpful is, they told me when I got my 
radiation pill not to get pregnant, but they didn’t really tell me ahead of 
time not to get pregnant, so in theory, I could have been a little pregnant at 
the time of getting the pill and not even known it, so I think hearing about 
that more in advance and hearing about my options, my birth control 
method options, would have been very helpful. You won’t be allowed to be 
pregnant in three months from now, so here’s what you can do that’s 
going to be compatible with your treatment plan in the meantime”     
Patient 5.  
 
Some providers suggest an ongoing screening process, with reassessment at 
every visit, periodically during treatment, or at the end of treatment.  
 
Providers differ as to the utility of incorporating this screening process into the 
electronic medical record. Generally, providers find adding new processes to the 
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electronic medical record to be beneficial, but providers vary as to the best 
location for contraception screening and referral. Some recommended an 
automatic notification or “pop-up”, while others prefer incorporating it into their 
documentation template:  
“Unless it’s in EPIC, unless there’s a hard stop… Unless there’s 
something easy to document, then it just doesn’t happen… Not a hard 
stop that you can’t close a note. But there should be some type of 
reminder or stop…that will recognize the patient’s date, recognize the 
diagnosis” Provider 5, physician, surgical oncology.  
 
Nursing documentation has an existing location to record contraception and 
reproductive health discussions, but nurses report lacking sufficient training to 
perform this patient education:  
“It's in there, like safe sex practices in our teaching part of it, but I don’t 
click it, because I don’t do it… So that's already in there for you.  It's just a 
matter of me being educated so that I can do it… Not that I couldn’t 
educate myself, but I don’t really know” Provider 17, nurse, medical 
oncology. 
 
Providers commonly requested education about this screening tool to facilitate 
implementation:  
“If we have another live person telling us why we’re having to do 
something, ‘coz a lot of times, they’ll start these new things – these new 
protocols, and they don’t ever explain why we’re doing it, so then people 
don’t care to even try to fix what’s going on…we all are more willing to do 
it if we understood why” Provider 11, nurse, medical oncology. 
 
  
Education about this screening tool would ideally address any feelings or 
perceptions that this is sensitive information and educate providers that some 
patients may not want to discuss contraception: “like an orientation to the kind of 
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questions to ask in a sensitive way and then depending on the answers to those 
questions the resources that are available” Provider 12, physician, surgical 
oncology. Some providers request observed encounters with direct feedback with 
either simulated or real patients as part of the training process for discussing 
reproductive health. 
 
Providers commonly attest to the utility of an audit-feedback process to facilitate 
the implementation of a new process, in which a provider receives a 
measurement and feedback on his or her compliance with a process. Providers 
suggest that this type of audit-feedback process helps the providers assess for 
progress and appreciate the impact the new process has on their patients:  
“It has to be something that’s constantly reinforced and ideally, I think with 
some sort of a way to measuring outcome and to provide feedback on it is 
really helpful. If you can see your own metrics and how you're doing I think 
it really reinforces what we're trying to achieve and help to assess where 
are the deficits and where you’re doing well. So, some of performance 
feedback and the constant reinforcement” Provider 12, physician, surgical 
oncology. 
 
Providers and patients requested access to patient-facing resources to facilitate 
contraception screening and referral 
Providers feel that a combination of communication forms, most commonly 
verbal and written, help to cover all the necessary health information shared 
during a visit. Patients similarly value the use of a combination of communication 
forms to help understand and retain health information provided at visits. To 
support contraception screening and referral, providers recommend the 
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development of brief, simple patient-facing resources. Specifically, providers 
suggest a simple handout or brochure that discusses contraception methods, 
recommends use of contraception during treatment, and a referral phone 
number:  
“So I think it would have to be very simplified… And, you know, that you 
shouldn’t get pregnant for these reasons, what your options are for birth 
control, and a referral number... That would be like off the top of my head” 
Provider 17, nurse, medical oncology.  
 
One provider also suggests a section indicating that each patient’s situation is 
unique with encouragement to discuss her situation with her provider.  
  
The patient population at this institution is diverse, and many patients may not 
speak English or may have a limited education level that may impact care or the 
utility of written information, and emphasize the importance of offering written and 
verbal information in multiple languages: 
“A lot of our patients, either they don’t speak English... We have a very 
diverse population here, as you know, so people don’t – either they don’t 
speak English or not a lot of education, so it’s hard to just give out reading 
things, if they can’t read and you may not know that. A mix between the 
both would be helpful” Provider 11, nurse, medical oncology.  
 
 
Providers indicate that patient-facing resources must be available in multiple 
languages and communication strategies, including verbal, written/online, and 
video, to best facilitate contraception use. 
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4. Discussion 
Findings from the provider interviews suggest that providers understand the risk 
of a pregnancy during cancer treatment; however, most providers do not 
routinely incorporate contraception discussions into their care of young women 
with cancer due to a variety of reasons ranging from lack of clear responsibility 
for contraception to provider perceived lack of education. Findings from the 
patient interviews similarly reflect infrequent conversations around contraception 
for pregnancy prevention. Prior research suggests that contraception counseling 
and referral by oncology providers improve contraception utilization during 
cancer care (Maslow et al., 2014). The results of this study highlight challenges 
unique to the cancer care setting that may impact the implementation of 
contraception screening and referral at this center. These challenges relate back 
to the PARiHS framework for implementation, which assesses the strength of 
three main constructs of evidence, context, and facilitation, to guide success 
implementation an evidence-based recommendation into practice. 
 
Evidence 
Within PARiHS, the concept of evidence includes research, clinical and patient 
experiences, and local data (Rycroft-Malone, 2004). With research evidence, 
providers indicate a strong understanding of risks of pregnancy during treatment 
and that patients should avoid pregnancy during treatment. However, many 
providers voice their lack of sufficient knowledge of contraception which impacts 
39 
 
 
their comfort with initiating a conversation about contraception. Additionally, 
currently available national guidelines for oncology care contain minimal 
guidance for contraception during and after cancer care, which impacts 
providers’ incorporation of contraception screening and referral into their usual 
care (National Comprehensive Cancer Network, 2018). The National 
Comprehensive Cancer Network (NCCN) recently updated national guidelines for 
adolescents and young adults with cancer, recommending providers discuss 
contraception with patients prior to initiating therapy and providing some 
guidance as to safe and appropriate methods (National Comprehensive Cancer 
Network, 2018). However, these guidelines lack specific recommendations to 
identify appropriate providers to discuss contraception. The NCCN published 
these updated guidelines after the completion of participant interviews, and 
implementation of these recommendations may benefit from additional supports 
identified in this study. 
 
Many providers have not had formal training in contraception at any point in their 
medical education. Rather, providers use clinical experiences to guide 
knowledge and counseling about contraception, which may include inaccurate or 
outdated information. For example, several providers mistakenly attribute 
contraceptive properties to Lupron (“Lupron Depot (leuprolide acetate) injection 
prescribing information”), which may contribute to uncertainty regarding the need 
for concurrent contraception with Lupron administration. Providers utilize other 
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perceptions from their clinical experience that impact contraception care, 
including the assumption that all patients have already established a method of 
contraception with their primary care provider or the assumption that patients are 
abstinent at the time of their diagnosis.  
 
With regard to patient experience, patients infrequently recall contraception 
discussions with their oncology providers. Rather, providers recommended they 
avoid pregnancy during their cancer care but did not offer additional support or 
referral for contraception to help successfully prevent a pregnancy during this 
time. Prior research suggests that patients with cancer continue to engage in 
sexual activity and that those who receive contraception counseling from their 
oncology provider are more likely to utilize contraception during treatment. 
Improving contraception screening and referral by oncology providers would 
improve both patient experience and patient safety in the context of cancer 
treatment. Patients may not initiate contraception discussions with their providers 
for a variety of reasons, for example because patients lack clarity as to the 
appropriate provider with whom to discuss contraception. Providers should 
initiate these conversations with their patients in order to promote contraception 
utilization during treatment. 
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Context  
The PARiHS construct of context includes culture, leadership, and evaluation 
(Rycroft-Malone, 2004). The findings in this study suggested a strong general 
institutional culture for the utilization of interdisciplinary teamwork during cancer 
care. However, for contraception during cancer treatment, the findings from this 
study suggest a lack of interdisciplinary collaboration between oncology and 
reproductive health providers. For example, providers lacked knowledge of the 
services available at the institution’s gynecology department, including a complex 
contraception clinic which a provider participant specifically requested. Providers 
also suggest that contraception screening is not part of the cancer center’s 
culture:  
“I mean, yeah, there is no screening process.  I mean we do regular 
pregnancy tests.  When it's like refilling the medication or a certain 
treatment beginning, if they're coming in for chemo.  I don’t know.  I guess 
maybe it's not the culture for it to be our responsibility.  I mean we make 
sure they're not pregnant, but beyond that, it's not very strong…birth 
control focus” Provider 6, APC, medical oncology.  
 
Provider participants identified several specific barriers to contraception 
screening and referral, many of which suggest the importance of fostering 
expeditious interdisciplinary collaboration within the cancer center while clarifying 
roles and responsibilities for contraception, and improved collaboration between 
the cancer center and reproductive health providers to promote timely referrals 
and contraception initiation.  
 
With leadership, the findings from provider participants highlight a significant lack 
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of clarity of roles, which is an important factor of context within PARiHS (Rycroft-
Malone, 2004). Specifically, while providers generally agree that preventing 
pregnancy is important during cancer care, participants lacked consensus on the 
primary person responsible for addressing contraception. Patients are similarly 
uncertain as to with which provider to discuss contraception and other 
reproductive health issues, which reflects the impact of this lack of role clarity 
among providers. The implementation process for contraception screening and 
referral needs to establish clear roles that depend on the composition of a 
patient’s care team and change over time as a patient’s needs change. 
 
With evaluation, provider participants strongly valued receiving feedback on their 
progress with a new process, and voiced interest in having an audit-feedback 
component developed into the implementation of a contraception screening and 
referral process. Providers appreciated the ability to recognize the positive 
impact of a new process on their patients and to ensure they were achieving the 
desired goals and recognize this audit-feedback process in other areas of clinical 
care, such as receiving feedback on compliance with various recommended 
screening tools. Some providers recall the lack of motivation to sustain a new 
process without this feedback. Organizations could implement an audit-feedback 
process by querying electronic health records and assessing documentation of 
contraception screening through existing department quality improvement and 
assurance programs. 
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Facilitation 
The PARiHS construct of facilitation includes “the process of enabling the 
implementation of evidence into practice” by means of individual facilitators with 
particular skills, roles, and attributes that contribute to the implementation 
process (Rycroft-Malone, 2004). The findings of this study suggest that oncology 
providers commonly viewed primary care providers and gynecologists as the 
individuals most commonly addressing contraception among patients of this age 
range in a task-oriented aspect of care, separate from a patient’s overall cancer 
care. Providers were receptive to a more holistic approach to implementation of 
contraception screening and referral and highlighted the importance of 
developing a strong partnership between a few gynecologic providers to aid in 
the education, training and implementation of this practice. Many providers 
welcomed the implementation of an improved contraception screening and 
referral system and expressed interest in increasing their current knowledge 
about contraception as it pertains to their patients. Additionally, a few providers 
identified themselves after the completion of their interview as a potential 
provider-champion for contraception screening and referral in the cancer center 
moving forward. 
 
4.1. Suggestions for improvement 
The findings from this study identify areas for improvement in order to 
successfully implement contraception screening and referral in this cancer 
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center. These suggestions include improved education, availability of appropriate 
guidelines, and strengthened interdisciplinary teamwork for contraception 
screening and referral. 
 
Provider education 
Oncology providers should receive formal education during medical education 
about reproductive health issues to facilitate implementation of contraception 
screening and referral. This education should be specific to the provider’s role 
within the care team (i.e. perioperative management of contraception for surgical 
providers, medical considerations for contraception for medical providers, etc.). 
This education should be incorporated into training programs such as oncology 
fellowships and new provider orientation to the cancer center.  
 
Participants preferred a variety of educational formats and topics to address 
contraception in this population. These training and educational modalities 
should start with an interprofessional training program within the institution (i.e. 
training for all oncology providers and a separate but similar training to for 
nursing staff) and then continue training with the interprofessional team within 
clinical practice. Training programs should include reproductive health and 
contraception education to foster improved knowledge in new providers. 
 
Further research should address gynecologists’ and primary care providers’ 
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knowledge of the safety of contraceptive methods among women with cancer. 
Theses providers may also require training and education about these topics to 
best care for women’s reproductive health needs during cancer treatment, 
particularly in institutions without family planning providers trained in complex 
contraception.  
 
Availability of national guidelines for contraception during cancer treatment 
National guidelines for contraception for young women with cancer focus on 
assessment of current pregnancy status and provide guidance for fertility 
preservation counseling and referral, and the 2018 version of these guidelines 
offer providers some guidance for safe contraception during and after treatment; 
however, these guidelines offer little guidance around contraception screening 
and referral for the same population (National Comprehensive Cancer Network, 
2018). Expansion of these guidelines is necessary in order to support and 
standardize screening and referral practices. 
 
National oncologic organizations should expand guidelines to support 
contraception screening and referral among oncology providers. These 
guidelines should include specific recommendations regarding the need for 
contraception screening and referral in reproductive-aged women with cancer, 
how and when (including how frequently) to address contraception with these 
patients, and specific guidance on the need for contraception concurrently with 
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Lupron. Additionally, national reproductive health organizations should expand 
available guidelines to offer more specific guidance to gynecology providers to 
help facilitate safe and effective contraception utilization (as some patients recall 
obstetrician-gynecology providers lacked knowledge re: contraception during 
cancer). These guidelines would offer oncologic providers evidence-based 
consensus recommendations and resources to augment local educational 
interventions to improve provider knowledge around contraception. 
 
 
Improved interdisciplinary teamwork for streamlined referral for contraception 
Because teams vary between patients and over time, and a patient’s individual 
contraceptive needs may change over her treatment course, institutions should 
establish clear expectations and responsibilities to successfully implement a 
contraception screening and referral process. This process should also empower 
patients to ask questions about contraception and help patients identify the 
appropriate provider with whom to discuss contraception as she proceeds 
through care. For example, providers may empower patients to engage in 
contraception discussions with their providers by including verbal and written 
patient education at the start of treatment about the importance of contraception 
and encouraging her to discuss reproductive health questions with a designated 
care team member. Additionally, national organizations could include 
contraception in patient-facing resources that offer additional guidance and 
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support for these conversations. 
 
Additionally, individual institutions should develop guidelines related to 
contraception counseling and referral to help establish roles, responsibilities, and 
identification of resources and referral processes for expeditious care. Providers 
should then communicate these expectations and resources with patients in both 
written and verbal form using translation and interpretation when necessary to 
meet the needs of a diverse patient population. 
 
Oncology care teams need established streamlined referral processes and 
established relationships with colleagues specializing in contraception to facilitate 
contraception screening and referral. Providers and patients should have access 
to a point person, for example, a family planning provider trained in complex 
contraception, to assist with scheduling and answering questions related to 
contraception during care. Care teams should utilize an interdisciplinary 
approach to contraception, including the establishment of stronger collaboration 
with reproductive health providers and established contraception clinics with the 
oncology care teams. 
 
5. Limitations 
This study has several limitations. First, we recruited all provider and patient 
participants from one institution which may limit the transferability of these results 
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to other institutions. Specifically, this institution has an established gynecology 
clinic including full spectrum family planning services with fellowship-trained 
providers in family planning which may not represent all cancer centers. 
However, many provider participants were not aware of the scope of care offered 
in the family planning section. Additionally, our provider participants represented 
a range of disciplines which may limit transferability; however, in our 
interdisciplinary setting, this approach helped us comprehensively and effectively 
understand contraception screening and referral at our institution. Second, we 
excluded trainees from our provider recruitment given the transient nature of their 
time caring for patients; however, these trainees may offer additional 
perspectives and some patients identified trainees such as fellows as a trusted 
source during their care. Third, we did not recruit radiation oncology or oncologic 
pharmacy providers to our study. Lastly, we may have had response bias as the 
provider interviews were completed by an obstetrician-gynecologist. 
 
For patients, we restricted recruitment to English-speaking participants. 
Approximately 31% of all patients seen at this institution do not speak English as 
their primary language [Hospital Internal Statistics]. We anticipate that non-
English speaking patients have unique perspectives and barriers to contraception 
during cancer care, and while some of these factors may have been recognized 
by provider participants, additional patient barriers may exist. Additionally, we 
included patient participants aged 18 years and older; those patients younger 
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than 18 years likely have unique barriers as well that were not captured here. 
Lastly, patients were eligible for participation if they had completed treatment 
within the last 2 years. We extended the eligible length of time from treatment to 
assist with recruitment; however, this longer time period may contribute to recall 
bias. 
 
For both patients and participants, this study may have had selection bias based 
the participants willing and able to engage in an interview. We were able to 
obtain a variety of information about current practices and experiences from 
providers and patients, respectively, and therefore believe our recruitment 
strategy facilitated a range of perspectives from our participants in this 
exploratory study. 
 
6. Conclusion 
For young women with cancer, a pregnancy during treatment could result in 
detrimental effects on both her treatment and on a developing fetus. 
Contraception screening and referral in the oncology setting is crucial to prevent 
harm, and contraception counseling by oncology providers appears to improve 
contraception utilization during treatment. Many barriers exist to this practice, 
including lack of education of oncology providers on contraception, lack of clear 
roles for contraception screening among oncology providers, and lack of clear 
national guidelines for incorporation of this screening into practice. Cancer 
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centers should address these barriers locally in future implementation of 
contraception screening and referral and national organizations should work to 
develop guidelines to inform and support this process in clinical practice. Future 
studies should address implementation of various strategies to improve 
contraception screening and referral in the cancer setting. 
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Tables 
 
Table 1. Provider Demographics (n=19) 
Characteristic N (%) or median (range) 
Age (median, in years) 42 (28-63) 
Gender  
 Female 
 Male   
 
14 (74%) 
5 (26%) 
Race 
   White 
   Asian 
 
16 (84%) 
3 (16%) 
Religion 
   Christian/Catholic 
   Other* 
   None 
 
8 (42%) 
4 (21%) 
7 (37%) 
Provider Role 
   Physician 
   Advanced Practice 
Clinician 
   Registered Nurse 
 
11 (58%) 
4 (21%) 
4 (21%) 
Provider Specialty 
  Surgical** 
  Medical  
 
8 (53%) 
7 (47%) 
Years of work at this 
cancer center 
  <10 
  10-20 years 
  30-35 years 
 
12 (63%) 
3 (16%) 
3 (16%) 
*Other includes Judaism, Hindu 
**Surgical providers include surgical oncology, gynecologic oncology, oral 
maxillofacial oncology, colorectal surgery, and otolaryngology. Medical providers 
include hematology/oncology, endocrinology, dermatology 
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Table 2. Patient Demographics (n=20) 
Characteristic N (%) or median (range) 
Cancer type 
  Thyroid 
  Breast 
  Blood/Lymphoid cell 
  Connective tissue      
      (osteosarcoma) 
  Other* 
 
7 (35%) 
3 (15%) 
3 (15%) 
2 (10%) 
 
5 (25%) 
Age (median, in years) 34.5 (23-45) 
Age 
  <30 years 
  >30 years   
 
7 (35%) 
13 (65%) 
Race 
   White 
   Black 
   Asian 
   Other 
 
10 (50%) 
3 (15%) 
3 (15%) 
4 (20%) 
Religion 
   Christian/Catholic 
   Muslim 
   Other 
   None 
 
9 (45%) 
2 (10%) 
2 (10%) 
7 (35%) 
Relationship status 
  Single 
  Partnered 
  Married 
  Widowed 
 
8 (40%) 
7 (35%) 
4 (20%) 
1 (5%) 
Previous children 
  Yes 
  No 
Median parity (with prior 
children) 
 
10 (50%) 
10 (50%) 
 
1.5 children (1-3) 
Highest Completed 
Education  
  High school diploma/GED 
  Some college 
  2-year college 
  4-year college/university 
  Graduate school 
 
 
2 (10%) 
7 (35%) 
1 (5%) 
8 (40%) 
2 (10%) 
*Other includes melanoma, brain, Ewing’s sarcoma, bladder/stomach, and oral 
cancers 
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